Buchet Delphine, Baron-Van Evercooren Anne
INSERM, U975, Paris, F-75013, France; Université Pierre et Marie Curie-Paris6, UMR S975. Paris, F-75013, France.
Neurosci Lett. 2009 Jun 12;456(3):112-9. doi: 10.1016/j.neulet.2008.09.086. Epub 2009 Jan 21.
Cell therapy appears as an exciting strategy for myelin repair in pathologies where oligodendrocytes are deficient or impaired, such as leucodystrophies and multiple sclerosis. Many studies indicate that several types of rodent cells, including neural stem and progenitor cells, play a beneficial role after grafting and induce functional recovery in animal models of myelin disorders. However, the difficulties to commit human neural stem cells towards the oligodendroglial lineage have long hampered human cell-based therapy for these diseases. In this review, we present recent advances in the field and discuss the various strategies that helped overcome the challenge of human oligodendroglial differentiation.
在少突胶质细胞缺乏或受损的疾病（如脑白质营养不良和多发性硬化症）中，细胞疗法似乎是一种令人兴奋的髓鞘修复策略。许多研究表明，包括神经干细胞和祖细胞在内的几种啮齿动物细胞类型，在移植后发挥有益作用，并在髓鞘疾病的动物模型中诱导功能恢复。然而，长期以来，将人类神经干细胞定向分化为少突胶质细胞谱系的困难一直阻碍着这些疾病基于人类细胞的治疗。在这篇综述中，我们介绍了该领域的最新进展，并讨论了有助于克服人类少突胶质细胞分化挑战的各种策略。
